Orphazyme predicts EU rejection after meeting with CHMP
![Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13576335.ece/ALTERNATES/schema-16_9/doc7ix60hajlsj1c421i3pd.jpg)
An indicative vote taken on Wednesday by the CHMP, an expert panel that is part of the European Medicines Agency, did not result in a majority in favor of recommending Orphazyme’s candidate arimoclomol for approval in the region. The CHMP (Committee for Medicinal Products for Human Use) was considering arimoclomol for the indication Niemann Pick type C, a rare metabolic disease also known as NPC.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme elects new board member
For subscribers
Orphazyme gets investor backing for fundraising round
For subscribers